The Effect of Thionamide to TRH, TSH, IL-4, T-REG, and Anti-TPO in Graves’ Disease

Eva Decroli, Dwitya Elvira, Dinda Aprilia


The most common cause of hyperthyroidism is Graves' disease. TRH and TSH are hormonal factors that modulate and control thyroid function in Graves' disease. In the immunological aspect, Graves' disease is played by the role of T-reg, IL-4, and anti-TPO. Graves' disease treatment goal is to inhibit thyroid hormone secretion by administering thionamide. The evaluation of this treatment is its hormonal and immunological aspects. To describe the effect of thionamide on serum TRH, TSH, IL-4, T-reg, and anti-TPO levels in Graves' disease. This study is a clinical trial study in 25 study participants. All study participants were given thionamide, namely PTU 300mg for three months and blood samples were taken for laboratory tests. Serum TRH, TSH, IL-4, T-reg FOXP3, and anti-TPO levels were examined by ELISA. The mean levels at the beginning and after three months of therapy are: serum TRH 92.589pg/mL and 115.944pg/mL; serum TSH 0.041mU/L and 0.223mU/L; serum IL-4 19.759pg/mL and 23.040pg/mL; T-reg FOXP3 gene polymorphism 0.621ng/mL and 0.518 ng/mL; serum anti-TPO 2697.539pg/mL and 2604.710pg/mL. Increased levels of serum TRH and TSH levels were statistically significant. The change in serum IL-4, T-reg FOXP3 gene polymorphism, and anti-TPO levels were not statistically significant. The administration of thionamide in Graves' disease for three months will significantly decrease Wayne index and serum FT4 levels, increase serum TRH and TSH levels.


TRH, TSH, T-reg, IL-4, anti-TPO

Full Text:



Alkemade A., 2015, ‘Thyroid hormone and the developing hypothalamus’. Front Neuroanat. 9(15), 1–9.

Davies T., Laurberg P., and Bahn R., 2011, ‘Hyperthyroid Disorders’, in Melmed S, Polonsky K, Larsen R, Kronenberg H, Williams Textbook of Endocrinology, pp. 369-415, Elsevier.

Decroli E., Manaf A., and Syahbuddin S., 2014, ‘Immunologic and hormonal effects of propylthiouracil treatment using maintenance dose in Graves’ disease’, Acta Med Indones. 46(4), 314-319.

Elvira D., and Darwin E., 2017, ‘Role of pro-inflammatory and regulatory cytokines in pathogenesis of Graves’ disease in association with autoantibody thyroid and regulatory FoxP3 T-cells’, International Journal of Medical and Health Sciences. 11(3), 69-72.

Elvira D., 2016, ‘The role of T-regulatory expression in autoimmune thyroid disease and its association with thyroid antibody’, Journal of Autoimmune Disorders. 2(2), 19.

Guissouma H., Dupre SM., Becker, N., Jeannin E., Seugnet, I., and Desvergne B., 2002, ‘Feedback on hypothalamic TRH transcription is dependent on thyroid hormone receptor N terminus’, Mol Endocrinol. 15(7), 1652–66.

Humar M., Dohrmann H., Stein P., Andriopoulos N., Goebel U., Roesslein, M., 2008, ‘Thionamides inhibit the transcription factor nuclear factor-B by suppression of Rac1 and inhibitor of B kinase ’, J Pharmacol Exp Ther. 324(3), 1037-44.

Laurberg P., Nygaard B., Andersen S., Carle A., Karmisholt J., Kerjbjerg, A., et al., 2014, ‘Association between TSH-receptor autoimmunity, hyperthyroidism, goitre, and orbitopathy in 208 patients included in the remission induction and sustenance in Graves’ disease study’, J Thyroid Res, 1-6.

Lillevang-Johansen M., Abrahamsen B., Jorgensen, H., Brix T., and Hegedus, 2017, ‘Excess mortality in treated and untreated hyperthyroidism is related to cumulative periods of low serum TSH’, J Clin Endocrinol Metab. 102(7), 2301-2309.

Ngo ST., Steyn FJ., and McCombe PA., 2014, ‘Gender differences in autoimmune disease’, Front Neuroendocrinol. 35(3), 347–69.

Schmidt F., and Braunbeck T., 2011. ‘Alterations along the hypothalamic-pituitary-thyroid axis of the zebrafish (Daniorerio) after exposure to propylthiouracil’, J Thyroid Res. 2011.

The Indonesian Society of Endocrinology, 2012, ‘Indonesian clinical practice guidelines for hyperthyroidism’, Journal of the ASEAN Federation of Endocrine Societies. 27(1), 1-5.

Voskuhl R., 2011, ‘Sex differences in autoimmune diseases’, Biol Sex Differ. 2(1), 1.

Wang PW., Chen IY., Juo SH., Hsi E., Liu RT., and Hsieh CJ., 2012, ‘Genotype and phenotype predictors of relapse of Graves’ disease after antithyroid drug withdrawal’. Eur Thyroid J. 1, 251-258.



  • There are currently no refbacks.

Copyright (c) 2019 Indonesian Journal of Pharmacy

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Indonesian J Pharm indexed by:

analytics View My Stats